This phase I study entitled “Phase I Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and Gene Edited to Eliminate Endogenous TCR and PD-1” involves 18 patients with refractory tumors, including melanoma (n = 6), synovial sarcoma (n = 6), and multiple myeloma (n = 6), without effective therapies. Here, PDCD1 is linked to AL amyloidosis.